Tuberculosis and Respiratory Diseases

  • 제72권1호
  • /
  • Pages.15-23
  • /
  • 2012
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지
DOI QR코드

DOI QR Code

Prognostic Factors and Scoring Systems for Non-Small Cell Lung Cancer Patients Harboring Brain Metastases Treated with Gamma Knife Radiosurgery

  • Eom, Jung-Seop (Department of Internal Medicine, Pusan National University School of Medicine) ;
  • Cho, Eun-Jung (Department of Internal Medicine, Pusan National University School of Medicine) ;
  • Baek, Dong-Hoon (Department of Internal Medicine, Pusan National University School of Medicine) ;
  • Lee, Kyung-Nam (Department of Internal Medicine, Pusan National University School of Medicine) ;
  • Shin, Kyung-Hwa (Department of Internal Medicine, Pusan National University School of Medicine) ;
  • Kim, Mi-Hyun (Department of Internal Medicine, Pusan National University School of Medicine) ;
  • Lee, Kwang-Ha (Department of Internal Medicine, Pusan National University School of Medicine) ;
  • Kim, Ki-Uk (Department of Internal Medicine, Pusan National University School of Medicine) ;
  • Park, Hye-Kyung (Department of Internal Medicine, Pusan National University School of Medicine) ;
  • Kim, Yun-Sung (Department of Internal Medicine, Pusan National University School of Medicine) ;
  • Park, Soon-Kew (Department of Internal Medicine, Pusan National University School of Medicine) ;
  • Cha, Seong-Heon (Department of Neurosurgery, Pusan National University School of Medicine) ;
  • Lee, Min-Ki (Department of Internal Medicine, Pusan National University School of Medicine)
  • 투고 : 2011.10.07
  • 심사 : 2011.11.09
  • 발행 : 2012.01.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: The survival of non-small cell lung cancer (NSCLC) patients with brain metastases is reported to be 3~6 months even with aggressive treatment. Some patients have very short survival after aggressive treatment and reliable prognostic scoring systems for patients with cancer have a strong correlation with outcome, often supporting decision making and treatment recommendations. Methods: A total of one hundred twenty two NSCLC patients with brain metastases who received gamma knife radiosurgery (GKRS) were analyzed. Survival analysis was calculated in all patients for thirteen available prognostic factors and four prognostic scoring systems: score index for radiosurgery (SIR), recursive partitioning analysis (RPA), graded prognostic assessment (GPA), and basic score for brain metastases (BSBM). Results: Age, Karnofsky performance status, largest brain lesion volume, systemic chemotherapy, primary tumor control, and medication of epidermal growth factor receptor tyrosine kinase inhibitor were statistically independent prognostic factors for survival. A multivariate model of SIR and RPA identified significant differences between each group of scores. We found that three-tiered indices such as SIR and RPA are more useful than four-tiered scoring systems (GPA and BSBM). Conclusion: There is little value of RPA class III (most unfavorable group) for the same results of 6-month and 1-year survival rate. Thus, SIR is the most useful index to sort out patients with poorer prognosis. Further prospective trials should be performed to develop a new molecular- and gene-based prognostic index model.

키워드

참고문헌

  1. Pizzocaro G, Ravasi GL. Surgical treatment of carcinoma of the esophagus and of the cardia: evaluation of the immediate and remote results. Tumori 1970;56:279-89.
  2. Flannery TW, Suntharalingam M, Kwok Y, Koffman BH, Amin PP, Chin LS, et al. Gamma knife stereotactic radiosurgery for synchronous versus metachronous solitary brain metastases from non-small cell lung cancer. Lung Cancer 2003;42:327-33.
  3. Komaki R, Cox JD, Stark R. Frequency of brain metastasis in adenocarcinoma and large cell carcinoma of the lung: correlation with survival. Int J Radiat Oncol Biol Phys 1983;9:1467-70.
  4. Jacot W, Quantin X, Boher JM, Andre F, Moreau L, Gainet M, et al. Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO analysis of prognostic factors. Br J Cancer 2001;84:903-9.
  5. Nieder C, Thamm R, Astner ST, Molls M. Prediction of very short survival in patients with brain metastases from non-small cell lung cancer. Cancer Ther 2008;6: 163-6.
  6. Pan HC, Sheehan J, Stroila M, Steiner M, Steiner L. Gamma knife surgery for brain metastases from lung cancer. J Neurosurg 2005;102 Suppl:128-33.
  7. Nieder C, Bremnes RM, Andratschke NH. Prognostic scores in patients with brain metastases from non-small cell lung cancer. J Thorac Oncol 2009;4:1337-41.
  8. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37:745-51.
  9. Weltman E, Salvajoli JV, Brandt RA, de Morais Hanriot R, Prisco FE, Cruz JC, et al. Radiosurgery for brain metastases: a score index for predicting prognosis. Int J Radiat Oncol Biol Phys 2000;46:1155-61.
  10. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 2008;70:510-4.
  11. Lorenzoni J, Devriendt D, Massager N, David P, Ruíz S, Vanderlinden B, et al. Radiosurgery for treatment of brain metastases: estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys 2004;60:218-24.
  12. Vallières E, Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, et al. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2009;4:1049-
  13. Rades D, Schild SE, Lohynska R, Veninga T, Stalpers LJ, Dunst J. Two radiation regimens and prognostic factors for brain metastases in nonsmall cell lung cancer patients. Cancer 2007;110:1077-82.
  14. Mariya Y, Sekizawa G, Matsuoka Y, Seki H, Sugawara T. Outcome of stereotactic radiosurgery for patients with non-small cell lung cancer metastatic to the brain. J Radiat Res (Tokyo) 2010;51:333-42.
  15. Pan HC, Sheehan J, Stroila M, Steiner M, Steiner L. Gamma knife surgery for brain metastases from lung cancer. J Neurosurg 2005;102 Suppl:128-33.
  16. Griffin TW, Pajak TF, Gillespie BW, Davis LW, Brady LW, Rubin P, et al. Predicting the response of head and neck cancers to radiation therapy with a multivariate modelling system: an analysis of the RTOG head and neck registry. Int J Radiat Oncol Biol Phys 1984;10:481-7.
  17. Weissman DE. Glucocorticoid treatment for brain metastases and epidural spinal cord compression: a review. J Clin Oncol 1988;6:543-51.
  18. Gülbaş H, Erkal HS, Serin M. The use of recursive partitioning analysis grouping in patients with brain metastases from non-small-cell lung cancer. Jpn J Clin Oncol 2006;36:193-6.
  19. Rodrigus P, de Brouwer P, Raaymakers E. Brain metastases and non-small cell lung cancer. Prognostic factors and correlation with survival after irradiation. Lung Cancer 2001;32:129-36.
  20. Gow CH, Chien CR, Chang YL, Chiu YH, Kuo SH, Shih JY, et al. Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response. Clin Cancer Res 2008;14:162-8.
  21. Lind JS, Lagerwaard FJ, Smit EF, Senan S. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2009;74:1391-6.
  22. Altavilla G, Arrigo C, Santarpia MC, Galletti G, Picone G, Marabello G, et al. Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases. J Neurooncol 2008;90:31-3.
  23. Shimato S, Mitsudomi T, Kosaka T, Yatabe Y, Wakabayashi T, Mizuno M, et al. EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. Neuro Oncol 2006;8:137-44.
  24. Eichler AF, Kahle KT, Wang DL, Joshi VA, Willers H, Engelman JA, et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol 2010;12:1193-9.